Wilson's new company, Philadelphia-based Gemma Biotherapeutics, plans to start testing gene therapies in Brazil this year.

T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.

Since the discovery of penicillin nearly a century ago, antimicrobial resistance (AMR) has become a stealthy, pervasive enemy ...

CureDuchenne is investing $1 million in Entos Pharmaceuticals to support the development of a new DMD gene therapy.